Richard Nieman - 31 Jan 2023 Form 4 Insider Report for Lyra Therapeutics, Inc. (LYRA)

Role
Chief Medical Officer
Signature
/s/ Jason Cavalier, Attorney-in-Fact for Richard Nieman, M.D.
Issuer symbol
LYRA
Transactions as of
31 Jan 2023
Net transactions value
$0
Form type
4
Filing time
02 Feb 2023, 16:08:35 UTC
Previous filing
12 Jul 2022
Next filing
01 Feb 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LYRA Stock Option Award $0 +55,537 $0.000000 55,537 31 Jan 2023 Common Stock 55,537 $2.85 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2023.